secwatch.observer — SEC 8-K summary
======================================

Issuer:     GYRE THERAPEUTICS, INC. (GYRE)
CIK:        0001124105
Form:       8-K
Filed at:   2026-03-12T23:59:59+00:00
Accession:  0001193125-26-102700
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gyre Therapeutics FY2025 revenue up 10% to $116.6M; net income down; guides FY2026 lower
--------------------------------------------------------------------------------

- Full-year 2025 revenue $116.6M (+10.2% YoY); net income $9.9M vs $17.9M; non-GAAP adj. net income $18.9M vs $16.9M.
- Q4 2025 revenue $37.2M (+33.3% YoY); net loss $1.4M vs income $0.6M; non-GAAP adj. net income $4.3M vs $1.1M.
- FY2026 revenue guidance $100.5M–$111.0M, a decline of 4.8%–13.8% vs 2025, citing regulatory priorities and market dynamics.
- Agreed to acquire Cullgen in ~$300M all-stock deal; transaction expected to close Q2 2026, adding protein degrader platform.
- Hydronidone NDA for conditional approval in China (CHB fibrosis) planned H1 2026; U.S. IND for MASH fibrosis targeted in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1124105/000119312526102700/0001193125-26-102700-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1124105/000119312526102700/gyre-20260312.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-102700

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer